Societal CDMO, Inc.

Revenue for Q3 2023 was $23.6 million versus $21.6 million in Q3 2022. Net loss was $4.6 million, or $0.05 per diluted share, versus a net loss of $3.3 million, or $0.06 per diluted share, last year. Adjusted EBITDA was $2.8 million versus $3.8 million a year ago. For the first nine months of 2023, revenue was $66.9 million versus $65.9 million, net loss was $12.5 million versus $10.7 million, and adjusted EBITDA was $6.3 million versus $10.6 million. Management reset 2023 guidance to revenue of $92 million-$94 million and adjusted EBITDA of $11.5 million-$13 million.

David Enloe framed the quarter as a period of both operational progress and defensive financial moves. He highlighted the DEA Schedule 1 license for psychedelic manufacturing, new customer project wins, the first NIH government contract, and a renewed push toward later-stage programs that are more profitable. His tone was cautiously optimistic, emphasizing that the company is repositioning for steadier growth, positive cash flow, and eventual sustainable profitability.

Ryan Lake said higher commercial manufacturing revenue, especially from Teva, along with Lannett and the first Otsuka shipments, helped offset softer Novartis and InfectoPharm volumes. He pointed to higher costs from the new aseptic fill/finish line and $0.7 million of restructuring costs in both cost of sales and SG&A for the quarter, while interest expense fell to $3 million from $3.6 million due to lower principal and lower rates under refinanced debt. He also said gross margin should improve into the high 20% range, with full-year gross margin around 19%-20%, and reiterated expectations for positive cash flow from operations and free cash flow positivity in 2024.

Analysts focused on whether the early-stage cuts were temporary, when restructuring savings would show up, the timing of late-phase programs ramping, and whether the psychedelic opportunity could produce near-term contracts. Management said the early-stage pullback is a response to sponsors delaying programs and can be reversed when conditions improve, that savings should largely begin in Q1 next year, and that the late-stage programs are already contributing to revenue with tech transfers typically taking 18 months to 2.5 years. On psychedelics, management said the market is still early and financing-constrained, but that it has had several conversations and is actively building awareness.